Business Description
Inhibrx Biosciences Inc
NAICS : 541714
SIC : 2834
ISIN : US45720N1037
Total Employee Number:
110Description
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.89 | |||||
Equity-to-Asset | -0.11 | |||||
Debt-to-Equity | -8.6 | |||||
Debt-to-EBITDA | -1.58 | |||||
Piotroski F-Score | 1/9 | |||||
Altman Z-Score | 0.72 | |||||
Beneish M-Score | 1.49 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -2.6 | |||||
3-Year EBITDA Growth Rate | -0.3 | |||||
3-Year EPS without NRI Growth Rate | -3.7 | |||||
3-Year FCF Growth Rate | -9.3 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 24.38 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 40.21 | |||||
9-Day RSI | 43.72 | |||||
14-Day RSI | 45.12 | |||||
3-1 Month Momentum % | 10.83 | |||||
6-1 Month Momentum % | 21.43 | |||||
12-1 Month Momentum % | 301.57 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 6.46 | |||||
Quick Ratio | 6.46 | |||||
Cash Ratio | 6.1 | |||||
Days Sales Outstanding | 53.42 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -0.8 | |||||
Shareholder Yield % | -7.02 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Operating Margin % | -9465.46 | |||||
Net Margin % | -10014.23 | |||||
EBITDA Margin % | -8832.46 | |||||
FCF Margin % | -10148.85 | |||||
OCF Margin % | -10148.08 | |||||
ROE % | -348.48 | |||||
ROA % | -67.62 | |||||
ROIC % | -549.61 | |||||
3-Year ROIIC % | -252.4 | |||||
ROC (Joel Greenblatt) % | -1134.88 | |||||
ROCE % | -74.74 | |||||
Years of Profitability over Past 10-Year | 1 | |||||
Moat Score | 6 | |||||
Tariff Resilience Score | 7 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 1094.77 | |||||
EV-to-EBIT | -11.68 | |||||
EV-to-EBITDA | -11.92 | |||||
EV-to-Revenue | 1052.62 | |||||
EV-to-FCF | -10.37 | |||||
Earnings Yield (Greenblatt) % | -8.56 | |||||
FCF Yield % | -9.78 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:INBX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Inhibrx Biosciences Inc Executives
DetailsGF Valueâ„¢
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 1.3 | ||
| EPS (TTM) ($) | -8.39 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 170.03 | ||
| 14-Day RSI | 45.12 | ||
| 14-Day ATR ($) | 7.429344 | ||
| 20-Day SMA ($) | 95.2565 | ||
| 12-1 Month Momentum % | 301.57 | ||
| 52-Week Range ($) | 20.55 - 155.29 | ||
| Shares Outstanding (Mil) | 14.67 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 1 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Inhibrx Biosciences Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Inhibrx Biosciences Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-13 | In 121 days | ||
| Second quarter earnings results for 2026 | 2026-08-13 | In 29 days | ||
| General meeting for 2025 | 2026-06-03 10:00 | 93.63 (-2.47%) | ||
| General meeting for 2025 | 2026-05-28 10:00 | 103.00 (-3.93%) | ||
| First quarter earnings results for 2026 | 2026-05-14 | 117.95 (+10.74%) | ||
| Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC | 2026-05-11 05:30 | 134.35 (+7.32%) | ||
| Inhibrx Biosciences Provides Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer | 2026-04-21 13:30 | 82.39 (-5.41%) | ||
| Annual report for 2025 | 2026-03-19 | 68.69 (+0.19%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-19 | 68.69 (+0.19%) | ||
| Third quarter earnings results for 2025 | 2025-11-14 | 74.62 (+2.22%) |
Show
Entries
Inhibrx Biosciences Inc Frequently Asked Questions
What is Inhibrx Biosciences Inc(INBX)'s stock price today?
The current price of INBX is $91.96. The 52 week high of INBX is $155.29 and 52 week low is $20.55.
When is next earnings date of Inhibrx Biosciences Inc(INBX)?
The next earnings date of Inhibrx Biosciences Inc(INBX) is 2026-08-13 Est..
Does Inhibrx Biosciences Inc(INBX) pay dividends? If so, how much?
Inhibrx Biosciences Inc(INBX) does not pay dividend.
Guru Commentaries on NAS:INBX
No articles.
Press Release
Articles on Inhibrx Biosciences Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers